These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24010675)

  • 21. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
    Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naltrexone in the treatment of alcohol dependence.
    Krystal JH; Cramer JA; Krol WF; Kirk GF; Rosenheck RA;
    N Engl J Med; 2001 Dec; 345(24):1734-9. PubMed ID: 11742047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence.
    Laaksonen E; Koski-Jännes A; Salaspuro M; Ahtinen H; Alho H
    Alcohol Alcohol; 2008; 43(1):53-61. PubMed ID: 17965444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
    Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
    Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
    Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
    Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial.
    Likhitsathian S; Uttawichai K; Booncharoen H; Wittayanookulluk A; Angkurawaranon C; Srisurapanont M
    Drug Alcohol Depend; 2013 Dec; 133(2):440-6. PubMed ID: 23906999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K; Bladström A; Torup L; Gual A; van den Brink W
    Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain.
    Southworth S; Peters J; Rock A; Pavliv L
    Clin Ther; 2009 Sep; 31(9):1922-35. PubMed ID: 19843482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse.
    O'Malley SS
    Alcohol Alcohol; 1996 Mar; 31 Suppl 1():77-81. PubMed ID: 8737005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
    O'Malley SS; Todtenkopf MS; Du Y; Ehrich E; Silverman BL
    Alcohol Clin Exp Res; 2018 Oct; 42(10):2011-2021. PubMed ID: 30055046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
    McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
    Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial.
    Guardia J; Caso C; Arias F; Gual A; Sanahuja J; Ramírez M; Mengual I; Gonzalvo B; Segura L; Trujols J; Casas M
    Alcohol Clin Exp Res; 2002 Sep; 26(9):1381-7. PubMed ID: 12351933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Addolorato G; Leggio L; Ferrulli A; Cardone S; Bedogni G; Caputo F; Gasbarrini G; Landolfi R;
    Alcohol Alcohol; 2011; 46(3):312-7. PubMed ID: 21414953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
    Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
    Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
    Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
    Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse.
    O'Malley SS
    Alcohol Alcohol Suppl; 1996 Mar; 31(1):77-81. PubMed ID: 9845042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
    O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
    Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.